Exosomes in kidney disease: From Pathophysiology to Diagnostic and Therapeutic Tools [0.03%]
外泌体与肾脏疾病：从病理生理到诊断和治疗工具
Juan He,Jianan Feng,Jin Zhao et al.
Juan He et al.
Background: Kidney disease is a significant global public health and economic burden, with unmet clinical requirements for early diagnostic biomarkers and targeted therapies. Exosomes, nanoscale lipid bilayer vesicles tha...
Hrushikesh Vikas Kulkarni,Shrikant Ramesh Mulay,Anil Bhanudas Gaikwad
Hrushikesh Vikas Kulkarni
Acute kidney injury (AKI) affects 10-15% of hospitalized patients, and nearly one-quarter progress to chronic kidney disease (CKD), reflecting a failure to recognize the temporally dynamic continuum linking these conditions. This review syn...
Hrushikesh Vikas Kulkarni,Shrikant Ramesh Mulay,Anil Bhanudas Gaikwad
Hrushikesh Vikas Kulkarni
Acute kidney injury (AKI) affects 10-15% of hospitalized patients, and nearly one-quarter progress to chronic kidney disease (CKD), reflecting a failure to recognize the temporally dynamic continuum linking these conditions. This review syn...
Regulatory Frameworks and Technical Bottlenecks for Clinical Translation of the Bioartificial Kidney [0.03%]
生物人工肾脏临床转化的监管框架和技术瓶颈
Leyla Sharafutdinova,Silvia M Mihăilă,Douwe Rigters et al.
Leyla Sharafutdinova et al.
Individualizing pharmacologic and non-pharmacologic therapy for CKD associated with diabetes [0.03%]
个体化治疗糖尿病肾病的药物与非药物疗法
Zurong Zhang,Li Li,Ming Yang et al.
Zurong Zhang et al.
Diabetic kidney disease (DKD) now has more proven kidney-protective therapies than at any previous time: renin-angiotensin system inhibitors (RASi), sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonist...
Sepsis and Infectious Outcomes for GLP-r Agonists in CKD plus Type 2 Diabetes [0.03%]
慢性肾病合并2型糖尿病患者中胰高血糖素样肽受体激动剂的脓毒症及感染相关结局研究
Yu-Yang Tseng,Hsien-Yi Wang,Jui-Yi Chen et al.
Yu-Yang Tseng et al.
Background: Chronic kidney disease (CKD) is associated with a higher risk of sepsis and poorer clinical outcomes compared to the general population. While GLP-1 receptor agonists (GLP-1RA) may confer protective effects ag...
CKD-associated osteoporosis in patients with CKD G4-5D: a pragmatic treatment approach [0.03%]
慢性肾病4-5期患者的肾脏病相关性骨质疏松症的务实治疗方法
Pieter Evenepoel,Hanne Skou Jørgensen;European Renal Osteodystrophy (EUROD) Initiative of the Chronic kidney disease – mineral and bone disorder working group of the European Renal Association
Pieter Evenepoel
Fracture risk increases along the progression of chronic kidney disease (CKD) to become several-fold higher in patients with CKD G4-5D as compared to the kidney-healthy background population matched for age and sex. In 2023, Kidney Disease ...
Urinary Dickkopf-3 as a biomarker for kidney-function decline: a systematic review and meta-analysis [0.03%]
尿液Dickkopf-3作为肾脏功能减退生物标志物的系统评价和meta分析
Yiwei Shang,Binqi Wang,Yue Huang et al.
Yiwei Shang et al.
Background: Urinary Dickkopf-3 (uDKK3) is a tubular-stress glycoprotein linked experimentally to tubular injury, context-dependent Wnt signaling and tubulointerstitial remodeling. Human studies now span CKD, kidney histol...
Dapagliflozin preserves kidney function and reduces albuminuria in children with chronic kidney disease [0.03%]
达格列净可保护儿童慢性肾脏病患者的肾功能和降低蛋白尿
Farahnak Assadi,Elham Bidabadi,Mojgan Mazaheri et al.
Farahnak Assadi et al.
Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce CKD progression in adults; but pediatric evidence remains limited. We evaluated dapagliflozin in children with non-diabetic CKD. ...
Stefan Neuhaus,Danilo Fliser,Stefan Schunk
Stefan Neuhaus
Approximately 750 million people worldwide suffer from chronic kidney diseases (CKD)-a leading cause of cardiovascular morbidity and premature mortality-but early identification of progressive kidney function decline in patients at risk is ...